Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions.
about
Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancerRadioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropinClinical significance of diffuse intrathoracic uptake on post-therapy I-131 scans in thyroid cancer patients.Stimulated Serum Thyroglobulin Level at the Time of First Dose of Radioactive Iodine Therapy Is the Most Predictive Factor for Therapeutic Failure in Patients With Papillary Thyroid Carcinoma.Preoperative determination of serum thyroglobulin to identify patients with differentiated thyroid cancer who may present recurrence without increased thyroglobulin.New developments in the diagnosis and treatment of thyroid cancer.Is Recombinant Human TSH a Trigger for Graves' Orbitopathy?Multiple Bone Metastases in a Patient with Differentiated Thyroid Cancer (DTC): Complete resolution following thyroidectomy and four ablation doses of I-131The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre.Managing differentiated thyroid cancer.Acta Oncologica Lecture. Present status of the use of recombinant human TSH in thyroid cancer management.Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation.Star-Shaped Intense Uptake of ¹³¹I on Whole Body Scans Can Reflect Good Therapeutic Effects of Low-Dose Radioactive Iodine Treatment of 1.1 GBq.
P2860
Q24236576-B9C94175-F876-46CB-90F3-1E9437DB842EQ33399549-422946BA-0D50-4DEA-9382-E01DF0261487Q33669796-0DB43DCE-3A5A-4595-9EAE-77D9E5A4A4A5Q36064573-90F4B8C5-93A1-4541-A67E-C4861B1D5FCDQ37091804-A136A072-CE20-46C7-A185-5B63E9469CD5Q37238757-D16725AA-E870-4500-8D44-874A34210B7BQ37290852-70ECD90A-67D0-4B53-B375-38D5CD68F7ECQ41954378-EBD8B4C6-8ABF-4400-9E41-4787FCC51DC3Q42518097-263C5E28-AD5F-410E-B504-CF807D3D7907Q42777454-7885ADC9-E20C-47A1-8E58-C36047E180C1Q48557941-9D1A1099-D17B-4A00-A101-2AB96A7FF62EQ53666999-0B0EFF63-9A08-4212-9588-856AE8F96E73Q55422207-A5C7F510-D924-4970-90AA-C8C10A13B3D3
P2860
Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Using recombinant human TSH in ...... ategies and future directions.
@ast
Using recombinant human TSH in ...... ategies and future directions.
@en
Using recombinant human TSH in ...... ategies and future directions.
@nl
type
label
Using recombinant human TSH in ...... ategies and future directions.
@ast
Using recombinant human TSH in ...... ategies and future directions.
@en
Using recombinant human TSH in ...... ategies and future directions.
@nl
prefLabel
Using recombinant human TSH in ...... ategies and future directions.
@ast
Using recombinant human TSH in ...... ategies and future directions.
@en
Using recombinant human TSH in ...... ategies and future directions.
@nl
P356
P1433
P1476
Using recombinant human TSH in ...... ategies and future directions.
@en
P2093
Mazzaferri EL
P304
P356
10.1089/THY.2000.10.767
P577
2000-09-01T00:00:00Z